Neuronal injury-induced expression and release of apolipoprotein E in mixed neuron/glia co-cultures: Nuclear factor κB inhibitors reduce basal and lesion-induced secretion of apolipoprotein E

Neuroscience

Volumn 104, Issue 1, 2001, Pages 223-234

  Petegnief, V ^a   Saura, J ^a,b   De Gregorio Rocasolano, N ^a,c   Paul, S M ^a,b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Alzheimer's disease; Apolipoprotein E; Glial activation; Neuronal injury; NF B

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ACETYLSALICYLIC ACID; APOLIPOPROTEIN E; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DIZOCILPINE; GLIAL FIBRILLARY ACIDIC PROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN CELL; CELL ACTIVATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; EMBRYO; GLIA; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT;

ALZHEIMER DISEASE; ANIMALS; ANTIBODIES; APOLIPOPROTEINS E; CELL DEATH; CELL DIVISION; CELLS, CULTURED; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO; EXCITATORY AMINO ACID AGONISTS; GLIAL FIBRILLARY ACIDIC PROTEIN; MODELS, ANIMAL; N-METHYLASPARTATE; NERVE DEGENERATION; NEUROGLIA; NEURONS; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SYNAPTOPHYSIN; TIME FACTORS; UP-REGULATION;

EID: 0035836436     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(01)00046-X     Document Type: Article

References (88)

1. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NF-κB-dependent mechanism
2. Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene
3. Pro-inflammatory signaling: Last pieces in the NF-κB puzzle?
4. The NF-κB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation
5. Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease
6. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
7. Amyloid-beta peptide stimulates apolipoprotein E synthesis and release in a murine microglial cell line via an NF-κB-dependent mechanism
8. Non-steroidal anti-inflammatory drug use and Alzheimer's disease: A case-control study in Rochester, Minnesota, 1980 through 1984
9. Apolipoprotein E level in cerebrospinal fluid increases with aging
10. Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease
11. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease
12. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia
13. IL-1-induced iNOS expression in human astrocytes via NF-kappa B
14. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
15. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
16. Expression of the Alzheimer amyloid-promoting factors alpha1-antichymotrypsin and apolipoprotein E is induced in astrocytes by IL-1
17. Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes
18. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium
19. Proteasome blockers inhibit TNF-alpha release by lipopolysaccharide stimulated macrophages and microglia: Implications for HIV-1 dementia
20. Activation of nuclear factor-κB in the rat brain after transient focal ischemia
21. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein
22. Aβ42 is the predominant form of amyloid β-protein in the brains of short term survivors of head injury
23. Characterization of ameboid microglia isolated from developing mammalian brain
24. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
25. Is there a genetic basis for the deposition of β-amyloid after fatal head injury
26. Nuclear factor-κB/Rel proteins. A point of convergence of signalling pathways relevant in neuronal function and dysfunction
27. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation
28. Rapid proteolysis of IκB-alpha is necessary for activation of transcription factor NF-κB
29. Marked alterations in the cellular localisation and levels of apolipoprotein E following acute subdural haematoma in rat
30. Influence of apolipoprotein E genotype on neuronal damage and apoE immunoreactivity in human hippocampus following global ischemia
31. Selective alterations in the cellular distribution of apoliprotein E immunoreactivity following transient cerbral ischaemia in the rat
32. NSAIDs and incident Alzheimer's diseases. The Rotterdam study
33. Transcription factor NF-κB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease
34. Apolipoprotein-ε4 and head trauma: Synergistic or additive risks?
35. NF-κB activity is induced by neural cell adhesion molecule binding to neurons and astrocytes
36. Isoform-specific binding of apolipoprotein E to β amyloid
37. Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid
38. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease
39. The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease
40. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type
41. Candidate gene for chromosome 1 familial Alzheimer's disease locus
42. A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity
43. Synergistic effects of traumatic head injury and apolipoprotein-ε4 in patients with Alzheimer's disease
44. Brain inflammation in Alzheimer disease and the therapeutic implications
45. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's diseases: A review of 17 epidemiologic studies
46. Brain injury in a dish: A model for reactive gliosis
47. Truncated apoE in human brain: Fact or artefact?
48. Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease
49. Injury-induced synthesis and release of apoliprotein E and clusterin from rat neural cells
50. Head trauma as a risk factor for Alzheimer's disease: A collaborative reanalysis of case-control studies
51. Expression of apolipoprotein E mRNA in rat microglia
52. Apoliprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeld-Jakob disease
53. Differential IκB kinase activation and IκB-alpha degradation by interleukin-1beta and tumor necrosis factor-alpha in human U937 monocytic cells
54. Apolipoprotein E ε4 allele is associated with deposition of amyloid β-protein following head injury
55. Head injury and risk of Alzheimer's disease by apolipoprotein E genotype
56. NF-κB: A crucial transcription factor for glial and neuronal cell function
57. Neuroprotective efficacy and mechanisms of novel pyrrolopyrimidine lipid peroxidation inhibitors in the gerbil forebrain ischemia model
58. Dissociation of apolipoprotein and apolipoprotein receptor response to lesion in the rat brain: An in situ hybridization study
59. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of the NF-kappa B
60. Induction of NF-κB-like transcription factor in brain areas susceptible to kainate toxicity
61. Novel inhibitors of cytokine-induced IκB-alpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo
62. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
63. Astrocytic apoliprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning
64. Cloning of hippocampal poly(A) RNA sequences that increase after entorhinal cortex lesion in adult rat
65. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats
66. Human immunodeficiency virus type 1 Tat protein stimulates inducible nitric oxide synthase expression and nitric oxide production in microglial cultures
67. Effect of apolipoprotein E on neurite outgrowth and beta-amyloid-induced toxicity in developing rat primary hippocampal cultures
68. MatInd and MatInspector--new fast and versatile tools for detection of consensus matches in nucleotide sequence data
69. Signaling molecules and neuroglial activation in the injured central nervous system
70. Amyloid protein deposition in the brain after head injury: Implications for the pathogenesis of Alzheimer's disease
71. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene
72. Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease
73. Marked increases in concentrations of apoliprotein in the cerebrospinal fluid of poliovirus-infected macaques: Relations between apolipoprotein concentrations and severity of brain injury
74. Differential regulation of astrocytic mRNAs in the rat striatum after lesions of the cortex or substantia nigra
75. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease
76. Bradykinin induces interleukin-6 expression in astrocytes through activation of nuclear factor kappa-B
77. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
78. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
79. Apolipoprotein E and Alzheimer's disease: A genetic, molecular and neuroimaging review
80. ApoE immunoreactivity and microglial cells in Alzheimer's disease brain
81. Transient nuclear factor κB (NF-κB) activation stimulated by interleukin-1beta may be partly dependent on proteasome activity, but not phosphorylation and ubiquitination of the IκB-alpha molecule, in C6 glioma cells
82. Nepalolide A inhibits the expression of inducible nitric oxide synthase by modulating the degradation of IkappaB-bta in C6 glioma cells and rat primary astrocytes
83. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the aminoacid sequence of the apo-E isoform
84. Apoliprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid
85. Alzheimer's disease and soluble A beta
86. Cell culture models for reactive gliosis: New perspectives
87. Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease
88. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-beta